Making Manufacturing Sites Inspection-ready After the Pandemic Gap

Due to COVID-19, many pharmaceutical manufacturing sites have not experienced a regulatory inspection in several years. Raj Pai discusses how to ensure that Good Manufacturing Practices are in place.

Buyer Beware: Compliance Risks at Emerging Cellular and Gene Therapy Companies

Chris Fanelli explains how emerging cellular and gene therapy companies present unique challenges and unique opportunities from a compliance perspective. He explores some of the tools that buyers can use to assess GxP compliance at the due diligence and post-acquisition stages.

(more…)